Developer docs
API playgroundTry for free, no card

Search company profiles

CEVEC Pharmaceuticals

Full company profile

uuid000cddq

Namestring
CEVEC Pharmaceuticals
Websiteurl
cevec.com
Company typeenum
Private
Founded yearint
2003
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKöln, Germany
HQ citystring
Köln
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cell line development, viral vector manufacturing, gene therapy production, biopharmaceutical platforms, protein expression systems
Industry1 code
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Line Development for Biomanufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ELEVECTA™
Description

Producer cell line platform for AAV-based gene therapy manufacturing, addressing batch-to-batch variability from transient transfection methods, GMP-grade plasmid DNA supply chain bottlenecks, and scalability limitations.

selectscience.net
Core offering1 text field

CEVEC develops and supplies proprietary stable producer cell line platforms that enable biopharmaceutical manufacturers to produce viral vectors and complex therapeutic proteins at scale. Its core products — the ELEVECTA™ AAV producer cell line platform, the CAP™ adenovirus producer cell line, and the GOCHO™ expression platform for human-glycosylated monoclonal antibodies and therapeutic proteins — replace traditional transient transfection workflows with stable, single-clone manufacturing processes suitable for clinical and commercial bioproduction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Eliminates batch-to-batch variability inherent in transient transfection methods
+2 more records
Product overview1 text field

CEVEC Pharmaceuticals, acquired by Cytiva in 2022, offers a portfolio of cell line development products and services for biopharmaceutical manufacturing. The core offerings include the ELEVECTA™ producer cell line platform for AAV-based gene therapy production, the GOCHO™ platform for monoclonal antibody and protein production cell line development, and the CAP™ Ad cell line for adenovirus manufacturing. These platforms work together to provide end-to-end viral vector solutions addressing industry challenges around scalability, batch consistency, and supply chain bottlenecks in advanced therapy manufacturing.

Product and service3 records
1ELEVECTA™ Producer Cell Line Platform
CategoryViral vector manufacturing — AAV production
Description

A stable producer cell line platform for adeno-associated virus (AAV) manufacturing designed to replace traditional transient transfection with scalable, reproducible, single-clone AAV production for gene therapy developers, CDMOs, and biopharmaceutical manufacturers.

2CAP™ Ad Cell Line
CategoryViral vector manufacturing — Adenovirus production
Description

A stable producer cell line for adenoviral vector manufacturing, providing scalable and reproducible upstream production of adenovirus for cell and gene therapy, vaccine, and oncolytic applications.

3GOCHO™ Cell Line Platform
CategoryRecombinant protein and monoclonal antibody expression
Description

An expression platform based on stable human cell lines that produce therapeutic proteins and monoclonal antibodies with human glycosylation patterns, intended for biopharmaceutical developers requiring human-compatible post-translational modifications.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthersAnnounced on2022-01-01
Description

Cytiva acquired CEVEC Pharmaceuticals in 2022 to strengthen its cell line development capabilities. The acquisition expanded Cytiva's portfolio to include CEVEC's ELEVECTA™ producer cell line platform for AAV-based gene therapy manufacturing and CAP™ Ad cell line for adenovirus production.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GenScript ProBio provides cell line development services, viral vector manufacturing, and gene therapy CDMO services for biopharmaceutical customers. Directly comparable to CEVEC's offerings around producing host cell lines and viral vectors for therapeutic manufacturing.

TypeBroad incumbent
Description

Lonza is the largest contract development and manufacturing organization for cell and gene therapies, including viral vector manufacturing services. As a broad incumbent in viral vector process development, Lonza competes in offering end-to-end AAV and lentiviral production platforms similar to CEVEC's stable producer cell line approach.

TypeDirect peer
Description

Repligen provides bioprocessing tools and technologies used in viral vector and gene therapy manufacturing, including filtration, chromatography, and process analytics. Comparable as a specialized bioprocessing technology provider serving gene therapy CDMOs and developers.

4Cobra Biologics (Charles River Laboratories)
TypeDirect peer
Description

Cobra Biologics, now part of Charles River, provides plasmid DNA, viral vector, and cell line development services for gene therapy and vaccine manufacturers. Operates a directly comparable service offering to CEVEC's producer cell line platform across the AAV/adenovirus manufacturing space.

TypeBroad incumbent
Description

WuXi Biologics is a leading global CDMO with extensive capabilities in cell line development, biologics manufacturing, and viral vector services. Operates in similar end markets as CEVEC with both upstream process development platforms and full manufacturing services.

TypeBroad incumbent
Description

FujiFilm Diosynth Biotechnologies is a major CDMO with significant gene therapy and viral vector manufacturing capacity. Comparable to CEVEC in addressing the upstream viral vector production needs of gene therapy customers, including AAV and lentiviral platforms.

TypeBroad incumbent
Description

Catalent's Paragon Gene Therapy business provides viral vector manufacturing for AAV and lentivirus, and offers related process development technologies for gene therapy developers. Directly comparable as a services and technology provider for viral vector manufacturing customers.

TypeBroad incumbent
Description

Thermo Fisher offers viral vector and cell line development services through its pharma services division, providing both manufacturing services and supporting cell line technologies for gene therapy and biologics. Comparable to CEVEC as a top-tier bioprocessing tools and services provider serving AAV/mAb manufacturers.

9MilliporeSigma (Sigma-Aldrich / Merck KGaA Life Science)
TypeBroad incumbent
Description

MilliporeSigma is the life science arm of Merck KGaA, offering cell lines, viral vector production technologies, and bioprocessing consumables. Overlaps with CEVEC in upstream process development for AAV/adenovirus and in mAb cell line development.

TypeBroad incumbent
Description

Sartorius Stedim Biotech is a leading supplier of bioprocess equipment, consumables, and cell line development services for biologics and advanced therapies. Directly comparable to Cytiva/CEVEC's bioprocessing footprint serving both mAb and viral vector manufacturers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CEVEC Pharmaceuticals

Cell Line Development for Biomanufacturingcevec.com

CEVEC Pharmaceuticals firmographics

Firmographics
Name
CEVEC Pharmaceuticals
Website
https://cevec.com
Company type
Private
Founded year
2003
Operating status
Acquired
Headcount range
11–50 employees
Ownership category
akta.pro rank

CEVEC Pharmaceuticals industry classification

Industry
Product category
Cell Line Development for Biomanufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cell line development
  • Viral vector manufacturing
  • Gene therapy production
  • Biopharmaceutical platforms
  • Protein expression systems

Where CEVEC Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Köln
HQ country
Germany
HQ region
Europe

Markets served

CEVEC Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

CEVEC Pharmaceuticals product offering

Product offering

Core offering

CEVEC develops and supplies proprietary stable producer cell line platforms that enable biopharmaceutical manufacturers to produce viral vectors and complex therapeutic proteins at scale. Its core products — the ELEVECTA™ AAV producer cell line platform, the CAP™ adenovirus producer cell line, and the GOCHO™ expression platform for human-glycosylated monoclonal antibodies and therapeutic proteins — replace traditional transient transfection workflows with stable, single-clone manufacturing processes suitable for clinical and commercial bioproduction.

Product overview

CEVEC Pharmaceuticals, acquired by Cytiva in 2022, offers a portfolio of cell line development products and services for biopharmaceutical manufacturing. The core offerings include the ELEVECTA™ producer cell line platform for AAV-based gene therapy production, the GOCHO™ platform for monoclonal antibody and protein production cell line development, and the CAP™ Ad cell line for adenovirus manufacturing. These platforms work together to provide end-to-end viral vector solutions addressing industry challenges around scalability, batch consistency, and supply chain bottlenecks in advanced therapy manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • ELEVECTA™: Producer cell line platform for AAV-based gene therapy manufacturing, addressing batch-to-batch variability from transient transfection methods, GMP-grade plasmid DNA supply chain bottlenecks, and scalability limitations.

Products and services

  • ELEVECTA™ Producer Cell Line Platform A stable producer cell line platform for adeno-associated virus (AAV) manufacturing designed to replace traditional transient transfection with scalable, reproducible, single-clone AAV production for gene therapy developers, CDMOs, and biopharmaceutical manufacturers.
  • CAP™ Ad Cell Line A stable producer cell line for adenoviral vector manufacturing, providing scalable and reproducible upstream production of adenovirus for cell and gene therapy, vaccine, and oncolytic applications.
  • GOCHO™ Cell Line Platform An expression platform based on stable human cell lines that produce therapeutic proteins and monoclonal antibodies with human glycosylation patterns, intended for biopharmaceutical developers requiring human-compatible post-translational modifications.

Quantifiable outcome

  • Eliminates batch-to-batch variability inherent in transient transfection methods
  • +2 more outcomes

Companies that use CEVEC Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles1 record

CEVEC Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CEVEC Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CytivacoreOthers · 1 January 2022Cytiva acquired CEVEC Pharmaceuticals in 2022 to strengthen its cell line development capabilities. The acquisition expanded Cytiva's portfolio to include CEVEC's ELEVECTA™ producer cell line platform for AAV-based gene therapy manufacturing and CAP™ Ad cell line for adenovirus production.

Scale indicators2 records

Recent moves7 records

Expansion highlights4 records

CEVEC Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • GenScript ProBio: GenScript ProBio provides cell line development services, viral vector manufacturing, and gene therapy CDMO services for biopharmaceutical customers. Directly comparable to CEVEC's offerings around producing host cell lines and viral vectors for therapeutic manufacturing.
  • Repligen Corporation: Repligen provides bioprocessing tools and technologies used in viral vector and gene therapy manufacturing, including filtration, chromatography, and process analytics. Comparable as a specialized bioprocessing technology provider serving gene therapy CDMOs and developers.
  • Cobra Biologics (Charles River Laboratories): Cobra Biologics, now part of Charles River, provides plasmid DNA, viral vector, and cell line development services for gene therapy and vaccine manufacturers. Operates a directly comparable service offering to CEVEC's producer cell line platform across the AAV/adenovirus manufacturing space.

Broad incumbents

  • Lonza Cell & Gene Technologies: Lonza is the largest contract development and manufacturing organization for cell and gene therapies, including viral vector manufacturing services. As a broad incumbent in viral vector process development, Lonza competes in offering end-to-end AAV and lentiviral production platforms similar to CEVEC's stable producer cell line approach.
  • WuXi Biologics: WuXi Biologics is a leading global CDMO with extensive capabilities in cell line development, biologics manufacturing, and viral vector services. Operates in similar end markets as CEVEC with both upstream process development platforms and full manufacturing services.
  • FujiFilm Diosynth Biotechnologies: FujiFilm Diosynth Biotechnologies is a major CDMO with significant gene therapy and viral vector manufacturing capacity. Comparable to CEVEC in addressing the upstream viral vector production needs of gene therapy customers, including AAV and lentiviral platforms.
  • Catalent (Paragon Gene Therapy): Catalent's Paragon Gene Therapy business provides viral vector manufacturing for AAV and lentivirus, and offers related process development technologies for gene therapy developers. Directly comparable as a services and technology provider for viral vector manufacturing customers.
  • Thermo Fisher Scientific (Patheon / Olin): Thermo Fisher offers viral vector and cell line development services through its pharma services division, providing both manufacturing services and supporting cell line technologies for gene therapy and biologics. Comparable to CEVEC as a top-tier bioprocessing tools and services provider serving AAV/mAb manufacturers.
  • MilliporeSigma (Sigma-Aldrich / Merck KGaA Life Science): MilliporeSigma is the life science arm of Merck KGaA, offering cell lines, viral vector production technologies, and bioprocessing consumables. Overlaps with CEVEC in upstream process development for AAV/adenovirus and in mAb cell line development.
  • Sartorius Stedim Biotech: Sartorius Stedim Biotech is a leading supplier of bioprocess equipment, consumables, and cell line development services for biologics and advanced therapies. Directly comparable to Cytiva/CEVEC's bioprocessing footprint serving both mAb and viral vector manufacturers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

CEVEC Pharmaceuticals social profiles

Digital presence

CEVEC Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CEVEC Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

CEVEC Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CEVEC Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CEVEC Pharmaceuticals

What does CEVEC Pharmaceuticals do?

CEVEC develops and supplies proprietary stable producer cell line platforms that enable biopharmaceutical manufacturers to produce viral vectors and complex therapeutic proteins at scale. Its core products — the ELEVECTA™ AAV producer cell line platform, the CAP™ adenovirus producer cell line, and the GOCHO™ expression platform for human-glycosylated monoclonal antibodies and therapeutic proteins — replace traditional transient transfection workflows with stable, single-clone manufacturing processes suitable for clinical and commercial bioproduction.

When was CEVEC Pharmaceuticals founded?

CEVEC Pharmaceuticals was founded in 2003. It employs 11 to 50 people.

Where is CEVEC Pharmaceuticals based?

CEVEC Pharmaceuticals is headquartered in Köln, Germany, in the Europe region.

Who are CEVEC Pharmaceuticals's main competitors?

Direct peers on record are GenScript ProBio, Repligen Corporation and Cobra Biologics (Charles River Laboratories). Broad incumbents are Lonza Cell & Gene Technologies, WuXi Biologics, FujiFilm Diosynth Biotechnologies, Catalent (Paragon Gene Therapy), Thermo Fisher Scientific (Patheon / Olin), MilliporeSigma (Sigma-Aldrich / Merck KGaA Life Science) and Sartorius Stedim Biotech.

Does CEVEC Pharmaceuticals have an API?

No public API is recorded for CEVEC Pharmaceuticals.

What industry is CEVEC Pharmaceuticals in?

CEVEC Pharmaceuticals's product category is Cell Line Development for Biomanufacturing. Its primary akta.pro industry code is HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SelectScienceEnd-to-end viral vector offerings propel AAV-based therapy forwardCytiva has acquired CEVEC Pharmaceuticals and the life sciences business of Pall Corporation to build comprehensive end-to-end viral vector solutions for AAV-based gene therapy manufacturing. The company presented its ELEVECTA™ producer cell line platform as a solution to key industry challenges, including batch-to-batch variability from transient transfection methods, GMP-grade plasmid DNA supply chain bottlenecks with wait times exceeding six months, and scalability limitations in AAV production.YahooThe Genomic Medicine Revolution: Multi-Modality Approaches in Advanced TherapiesGenomic medicine is a top industry trend, with DNA- and RNA-based gene therapies for oncology growing from $1.4B in 2022 to $2.3B in 2023, forecast to reach $28B by 2029. Multi-modality approaches like AAVs, CRISPR, and LNPs are converging, and collaboration between academia and industry, such as Cytiva's acquisition of CEVEC, aims to scale production and reduce costs.PR NewswireViral Vector Production Market Value to Reach US$ 19.0 Bn by 2032: TMR StudyTransparency Market Research published a market study projecting the global viral vector production market to reach US$ 19.0 billion by 2032, growing at a compound annual growth rate of 28.3% between 2022 and 2032. Adeno-associated virus emerged as the leading vector type segment in 2021, driven by its use in vaccines and CRISPR/Cas9 delivery methods, while downstream processing was the dominant workflow segment. The report identifies key players including Thermo Fisher Scientific, Merck KGaA, and CEVEC Pharmaceuticals, with Asia Pacific projected to emerge as the dominant regional market.GlobeNewswireGMP Cytokines Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Application, and GeographyThe GMP cytokines market is projected to grow from US$84.72 million in 2019 to US$158.13 million in 2027, an 8.1% CAGR. Growth factors held the largest segment share in 2019, while TNF is expected to see the highest CAGR. Product launches, such as CEVEC and CellGenix's GMP TGF-1 in December 2019, are anticipated to boost growth.BioWorldRznomics on track for adenoviruses development planRznomics, a South Korean biotech, signed a clinical and commercial agreement with Cevec Pharmaceuticals to develop adenovirus-based gene therapies. The partnership will use Cevec's Cap technology for manufacturing and Rznomics' trans-splicing ribozyme technology for cancer indications.GlobeNewswireDGAP-News: CEVEC submits Biologics Master File (BB-MF) for CAP(R) Technology to the U.S. FDACEVEC Pharmaceuticals submitted a Biologics Master File for its CAP(R) human cell substrate to the U.S. FDA on October 27, 2016. The submission supports regulatory approval for CAP(R)-derived products and aims to establish CAP(R) technology as an industrial standard for viral vaccines, gene therapy vectors, and recombinant protein production.GlobeNewswireDGAP-News: CEVEC further strengthens organization to drive industrialization and commercialization of CAP(R) technologiesCEVEC Pharmaceuticals appointed Bart Bergstein to its Supervisory Board, replacing Rainer Christine. The company also formed two new Scientific Advisory Boards to support industrialization of its CAP(R)GT and CAP(R)Go technologies. CEO Frank Ubags said the appointments aim to accelerate growth and set new global standards in biopharmaceutical production.GlobeNewswireDGAP-News: CEVEC and Paragon Bioservices enter into comprehensive collaboration to roll out CAP(R) technologies in North AmericaCEVEC Pharmaceuticals and Paragon Bioservices signed a collaboration and license agreement to roll out CEVEC's CAP(R) gene therapy vector technologies in North America. Paragon will serve as CEVEC's preferred CDMO partner, and the companies will jointly develop scalable clinical production processes for AAV, AV, and LV vectors. Financial details were not disclosed.GlobeNewswireDGAP-News: CEVEC's CAP(R)GT sets a new standard through RCA-free production of adenoviral vectors for gene therapy applicationsCEVEC Pharmaceuticals announced its CAP(R)GT cell-expression system produces adenoviral vectors without replication-competent adenovirus (RCA). No RCAs were found in 5x10^10 virus particles, whereas HEK293-derived preparations contained 5-500 RCAs per 10^10 VPs. The company aims to replace HEK293 as the production host.